Is decreased liver attenuation on a CT with contrast significant in a patient with polycythemia vera (PV)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 10, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Decreased Liver Attenuation on Contrast CT in Polycythemia Vera

Yes, decreased liver attenuation on contrast-enhanced CT is significant and warrants further evaluation, but it cannot be reliably quantified on contrast studies and requires correlation with clinical context and additional imaging.

Critical Limitation of Contrast-Enhanced CT for Liver Attenuation

Contrast-enhanced CT is not useful for assessing liver attenuation or diagnosing hepatic steatosis because Hounsfield unit (HU) values are highly variable after contrast injection. 1

  • HU values on contrast-enhanced studies vary due to:

    • Contrast injection timing 1
    • Location of injection site 1
    • Protocol differences 1
    • Scan length 1
    • Patient's hemodynamic circulation 1

  • Unlike unenhanced CT, where specific HU thresholds correlate with steatosis severity, no validated thresholds exist for contrast-enhanced studies. 1

What Decreased Attenuation May Indicate

Hepatic Steatosis (Most Common)

  • On unenhanced CT, liver attenuation <40 HU correlates with ≥30% steatosis 1
  • Progressive attenuation decrease correlates with increasing fatty infiltration:
    • 64.4 HU = 0% fat 1
    • 59.1 HU = 1-25% fat 1
    • 41.9 HU = 26-50% fat 1
    • 25.0 HU = >50% fat 1

Ischemic Liver Injury (Critical to Exclude)

  • Ischemic hepatitis can cause hypoenhancement of liver parenchyma and is a serious condition that can progress to liver failure with high mortality. 1
  • Contrast-enhanced CT can identify ischemic hepatitis and shock liver 1
  • PV patients have increased thrombosis risk (16% arterial, 7% venous at diagnosis), including splanchnic vein thrombosis, which can cause hepatic ischemia 2, 3

Specific Considerations in Polycythemia Vera

Thrombotic Complications

  • PV carries substantial risk of unusual site thrombosis, including Budd-Chiari syndrome (hepatic vein thrombosis), which presents with hepatomegaly and altered liver enhancement. 2, 3
  • Splanchnic vein thrombosis occurs in PV and can affect hepatic perfusion 2, 3
  • Arterial thrombosis occurs in 16% and venous thrombosis in 7% of patients at or before diagnosis 2

Hepatic Congestion

  • Contrast-enhanced CT provides hemodynamic information including sequelae of portal hypertension or hepatic congestion 1
  • PV-related hyperviscosity and thrombotic events can lead to hepatic congestion 1, 2

Recommended Diagnostic Algorithm

Immediate Assessment

  1. Review the contrast-enhanced CT for:

    • Hepatic vein patency (exclude Budd-Chiari syndrome) 2, 3
    • Portal vein patency (exclude portal vein thrombosis) 2, 3
    • Splenic vein patency 2, 3
    • Heterogeneous enhancement patterns suggesting ischemia 1
    • Splenomegaly (present in 36% of PV patients) 2

  2. Correlate with clinical features:

    • Abdominal pain or discomfort 2
    • Liver function tests 1
    • Signs of hepatic congestion or portal hypertension 1

Follow-up Imaging

If decreased attenuation is noted on contrast CT and steatosis assessment is clinically indicated, obtain unenhanced CT or MRI without contrast for accurate quantification. 1

  • MRI without contrast is superior to CT for diagnosing and grading steatosis, with sensitivity 76.7-90.0% and specificity 87.1-91% for detecting ≥5% hepatic fat. 1
  • Unenhanced CT has 100% specificity and 82% sensitivity for moderate steatosis (≥30%) 1

Critical Pitfalls to Avoid

  • Do not attempt to quantify liver fat content using HU measurements from contrast-enhanced CT—the values are unreliable and not validated. 1
  • Do not dismiss decreased liver attenuation as insignificant without excluding thrombotic complications, particularly Budd-Chiari syndrome, which is a recognized complication of PV. 2, 3
  • Do not assume decreased attenuation equals benign steatosis—ischemic liver injury is life-threatening and requires urgent recognition. 1
  • Always assess hepatic and portal vein patency in PV patients with abnormal liver imaging, as splanchnic thrombosis can occur at unusual sites. 2, 3

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Can polycythemia vera have an onset in adulthood?
What are the causes of isolated polycythemia?
What is the difference in target hematocrit between secondary polycythemia and polycythemia vera (Polycthemia Vera)?
What blood tests are used to monitor Polycythemia vera?
What are the diagnostic criteria for Polycythemia Vera (PV) in a female?
Is a decrease in attenuation significant in a patient with polycythemia vera (PV) undergoing Doppler ultrasound?
Can a patient with a history of depression or anxiety take nortriptyline (tricyclic antidepressant) with magnesium supplements before bed?
What are common descriptions and causes of lightheadedness, and how is it managed in patients with a history of cardiovascular disease or those taking medications such as blood pressure (antihypertensive) medications?
What is the diagnostic and treatment approach for a patient suspected of having an underlying immune deficiency, presenting with symptoms and signs of immune deficiency?
What nutritional guidelines should a typical adult patient with type 2 diabetes follow to manage their condition effectively?
What is the next step in management for a patient with gastroesophageal reflux disease (GERD) who has completed five weeks of proton pump inhibitor (PPI) therapy with omeprazole (prilosec) 20 mg once daily and has shown improvement in symptoms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question